Cerecor Inc (CERC) Director Armistice Capital, Llc Buys 12,651 Shares of Stock

Share on StockTwits

Cerecor Inc (NASDAQ:CERC) Director Armistice Capital, Llc purchased 12,651 shares of the business’s stock in a transaction dated Friday, January 11th. The stock was bought at an average cost of $3.90 per share, with a total value of $49,338.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Armistice Capital, Llc also recently made the following trade(s):

  • On Wednesday, January 9th, Armistice Capital, Llc purchased 545 shares of Cerecor stock. The stock was bought at an average cost of $3.79 per share, with a total value of $2,065.55.
  • On Monday, January 7th, Armistice Capital, Llc purchased 6,504 shares of Cerecor stock. The stock was bought at an average cost of $3.65 per share, with a total value of $23,739.60.
  • On Friday, January 4th, Armistice Capital, Llc purchased 20,000 shares of Cerecor stock. The stock was bought at an average cost of $3.42 per share, with a total value of $68,400.00.
  • On Tuesday, December 31st, Armistice Capital, Llc purchased 12,300 shares of Cerecor stock. The stock was bought at an average cost of $3.18 per share, with a total value of $39,114.00.
  • On Saturday, December 28th, Armistice Capital, Llc purchased 26,499 shares of Cerecor stock. The stock was bought at an average cost of $3.12 per share, with a total value of $82,676.88.
  • On Monday, December 31st, Armistice Capital, Llc purchased 12,300 shares of Cerecor stock. The stock was bought at an average cost of $3.18 per share, with a total value of $39,114.00.
  • On Friday, December 28th, Armistice Capital, Llc purchased 26,499 shares of Cerecor stock. The stock was bought at an average cost of $3.12 per share, with a total value of $82,676.88.
  • On Monday, December 17th, Armistice Capital, Llc purchased 14,938 shares of Cerecor stock. The stock was bought at an average cost of $3.26 per share, with a total value of $48,697.88.
  • On Friday, December 14th, Armistice Capital, Llc purchased 28,032 shares of Cerecor stock. The stock was bought at an average cost of $3.33 per share, with a total value of $93,346.56.
  • On Monday, December 10th, Armistice Capital, Llc acquired 13,815 shares of Cerecor stock. The shares were acquired at an average cost of $3.36 per share, with a total value of $46,418.40.

NASDAQ:CERC traded up $0.01 during trading hours on Friday, hitting $3.90. 20,155 shares of the company’s stock traded hands, compared to its average volume of 44,688. The firm has a market capitalization of $154.25 million, a price-to-earnings ratio of 9.29 and a beta of 1.30. Cerecor Inc has a 52 week low of $2.36 and a 52 week high of $5.74. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.70 and a current ratio of 0.74.

Cerecor (NASDAQ:CERC) last posted its quarterly earnings data on Tuesday, November 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by ($0.14). The business had revenue of $4.08 million for the quarter, compared to the consensus estimate of $4.80 million. Cerecor had a negative net margin of 241.29% and a negative return on equity of 75.94%. Equities analysts forecast that Cerecor Inc will post -1.09 earnings per share for the current fiscal year.

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc boosted its stake in Cerecor by 10.1% during the third quarter. Vanguard Group Inc now owns 87,929 shares of the company’s stock valued at $411,000 after buying an additional 8,094 shares during the period. BlackRock Inc. boosted its stake in Cerecor by 630.4% during the second quarter. BlackRock Inc. now owns 27,520 shares of the company’s stock valued at $120,000 after buying an additional 23,752 shares during the period. Finally, Cambridge Investment Research Advisors Inc. bought a new stake in Cerecor during the third quarter valued at $169,000. 44.48% of the stock is owned by institutional investors.

Several equities research analysts recently issued reports on the company. TheStreet raised Cerecor from a “d” rating to a “c” rating in a research note on Monday, November 12th. ValuEngine raised Cerecor from a “hold” rating to a “buy” rating in a research note on Thursday, November 1st. Finally, LADENBURG THALM/SH SH assumed coverage on Cerecor in a research note on Thursday, December 20th. They set a “buy” rating and a $9.00 price objective for the company.

TRADEMARK VIOLATION WARNING: “Cerecor Inc (CERC) Director Armistice Capital, Llc Buys 12,651 Shares of Stock” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4072778/cerecor-inc-cerc-director-armistice-capital-llc-buys-12651-shares-of-stock.html.

Cerecor Company Profile

Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Veripred, and Ulesfia for the treatment of inflammation of the skin, joints, lungs, and other organs, as well as asthma, allergies, arthritis, and head lice infestation.

Recommended Story: Why is the Consumer Price Index (CPI) important?

Insider Buying and Selling by Quarter for Cerecor (NASDAQ:CERC)

Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Cerecor Inc  Director Armistice Capital, Llc Buys 12,651 Shares of Stock
Cerecor Inc Director Armistice Capital, Llc Buys 12,651 Shares of Stock
Forescout Technologies Inc  SVP Darren J. Milliken Sells 3,870 Shares of Stock
Forescout Technologies Inc SVP Darren J. Milliken Sells 3,870 Shares of Stock
Smart Sand  Stock Rating Lowered by Zacks Investment Research
Smart Sand Stock Rating Lowered by Zacks Investment Research
Capricor Therapeutics  Downgraded by Zacks Investment Research
Capricor Therapeutics Downgraded by Zacks Investment Research
Booking  Downgraded by Jefferies Financial Group
Booking Downgraded by Jefferies Financial Group
Bojangles  Downgraded by Zacks Investment Research
Bojangles Downgraded by Zacks Investment Research


Leave a Reply

© 2006-2019 Ticker Report